• Je něco špatně v tomto záznamu ?

Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram

D. Majera, Z. Skrott, J. Bouchal, J. Bartkova, D. Simkova, M. Gachechiladze, J. Steigerova, D. Kurfurstova, J. Gursky, G. Korinkova, K. Cwiertka, Z. Hodny, M. Mistrik, J. Bartek,

. 2019 ; 79 (4) : 352-362. [pub] 20181129

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045108

Grantová podpora
NV16-32030A MZ0 CEP - Centrální evidence projektů
NV16-32030A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Castration-resistant prostate cancer (PCa) represents a serious health challenge. Based on mechanistically-supported rationale we explored new therapeutic options based on clinically available drugs with anticancer effects, including inhibitors of PARP1 enzyme (PARPi), and histone deacetylases (vorinostat), respectively, and disulfiram (DSF, known as alcohol-abuse drug Antabuse) and its copper-chelating metabolite CuET that inhibit protein turnover. METHODS: Drugs and their combination with ionizing radiation (IR) were tested in various cytotoxicity assays in three human PCa cell lines including radio-resistant stem-cell like derived cells. Mechanistically, DNA damage repair, heat shock and unfolded protein response (UPR) pathways were assessed by immunofluorescence and immunoblotting. RESULTS: We observed enhanced sensitivity to PARPi/IR in PC3 cells consistent with lower homologous recombination (HR) repair. Vorinostat sensitized DU145 cells to PARPi/IR and decreased mutant p53. Vorinostat also impaired HR-mediated DNA repair, as determined by Rad51 foci formation and downregulation of TOPBP1 protein, and overcame radio-resistance of stem-cell like DU145-derived cells. All PCa models responded well to CuET or DSF combined with copper. We demonstrated that DSF interacts with copper in the culture media and forms adequate levels of CuET indicating that DSF/copper and CuET may be considered as comparable treatments. Both DSF/copper and CuET evoked hallmarks of UPR in PCa cells, documented by upregulation of ATF4, CHOP and phospho-eIF2α, with ensuing heat shock response encompassing activation of HSF1 and HSP70. Further enhancing the cytotoxicity of CuET, combination with an inhibitor of the anti-apoptotic protein survivin (YM155, currently undergoing clinical trials) promoted the UPR-induced toxicity, yielding synergistic effects of CuET and YM155. CONCLUSIONS: We propose that targeting genotoxic and proteotoxic stress responses by combinations of available drugs could inspire innovative strategies to treat castration-resistant PCa.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045108
003      
CZ-PrNML
005      
20220216131638.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.23741 $2 doi
035    __
$a (PubMed)30499118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Majera, Dusana $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
245    10
$a Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram / $c D. Majera, Z. Skrott, J. Bouchal, J. Bartkova, D. Simkova, M. Gachechiladze, J. Steigerova, D. Kurfurstova, J. Gursky, G. Korinkova, K. Cwiertka, Z. Hodny, M. Mistrik, J. Bartek,
520    9_
$a BACKGROUND: Castration-resistant prostate cancer (PCa) represents a serious health challenge. Based on mechanistically-supported rationale we explored new therapeutic options based on clinically available drugs with anticancer effects, including inhibitors of PARP1 enzyme (PARPi), and histone deacetylases (vorinostat), respectively, and disulfiram (DSF, known as alcohol-abuse drug Antabuse) and its copper-chelating metabolite CuET that inhibit protein turnover. METHODS: Drugs and their combination with ionizing radiation (IR) were tested in various cytotoxicity assays in three human PCa cell lines including radio-resistant stem-cell like derived cells. Mechanistically, DNA damage repair, heat shock and unfolded protein response (UPR) pathways were assessed by immunofluorescence and immunoblotting. RESULTS: We observed enhanced sensitivity to PARPi/IR in PC3 cells consistent with lower homologous recombination (HR) repair. Vorinostat sensitized DU145 cells to PARPi/IR and decreased mutant p53. Vorinostat also impaired HR-mediated DNA repair, as determined by Rad51 foci formation and downregulation of TOPBP1 protein, and overcame radio-resistance of stem-cell like DU145-derived cells. All PCa models responded well to CuET or DSF combined with copper. We demonstrated that DSF interacts with copper in the culture media and forms adequate levels of CuET indicating that DSF/copper and CuET may be considered as comparable treatments. Both DSF/copper and CuET evoked hallmarks of UPR in PCa cells, documented by upregulation of ATF4, CHOP and phospho-eIF2α, with ensuing heat shock response encompassing activation of HSF1 and HSP70. Further enhancing the cytotoxicity of CuET, combination with an inhibitor of the anti-apoptotic protein survivin (YM155, currently undergoing clinical trials) promoted the UPR-induced toxicity, yielding synergistic effects of CuET and YM155. CONCLUSIONS: We propose that targeting genotoxic and proteotoxic stress responses by combinations of available drugs could inspire innovative strategies to treat castration-resistant PCa.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a oprava DNA $x účinky léků $7 D004260
650    _2
$a disulfiram $x terapeutické užití $7 D004221
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a cílená molekulární terapie $x metody $7 D058990
650    _2
$a buňky PC-3 $7 D000078722
650    _2
$a fosfohydroláza PTEN $x genetika $7 D051059
650    _2
$a PARP inhibitory $x terapeutické užití $7 D000067856
650    _2
$a nádory prostaty $x farmakoterapie $7 D011471
650    _2
$a tolerance záření $7 D011836
650    _2
$a rekombinační oprava DNA $x účinky léků $7 D059767
650    _2
$a fyziologický stres $x účinky léků $x genetika $7 D013312
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a vorinostat $x terapeutické užití $7 D000077337
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skrott, Zdenek $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Bartkova, Jirina $u Danish Cancer Society Research Center, Copenhagen, Denmark. Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.
700    1_
$a Simkova, Dana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Gachechiladze, Mariam $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Steigerova, Jana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Kurfürstová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0269558
700    1_
$a Gursky, Jan $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Korinkova, Gabriela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Cwiertka, Karel $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic.
700    1_
$a Hodny, Zdenek $u Department of Genome Integrity, Institute of Molecular Genetics of the CAS, v.v.i., Prague, Czech Republic.
700    1_
$a Mistrik, Martin $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Bartek, Jiri $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Danish Cancer Society Research Center, Copenhagen, Denmark. Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. Department of Genome Integrity, Institute of Molecular Genetics of the CAS, v.v.i., Prague, Czech Republic.
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 79, č. 4 (2019), s. 352-362
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30499118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20220216131633 $b ABA008
999    __
$a ok $b bmc $g 1483377 $s 1083781
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 79 $c 4 $d 352-362 $e 20181129 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
GRA    __
$a NV15-28628A $a NV16-32030A $p MZ0 $p MZ0
GRA    __
$a NV15-28628A $a NV16-32030A $p MZ0 $p MZ0
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace